1. Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes.
- Author
-
Scaife, M, Pacienza, N, Au, B C Y, Wang, J C M, Devine, S, Scheid, E, Lee, C-J, Lopez-Perez, O, Neschadim, A, Fowler, D H, Foley, R, and Medin, J A
- Subjects
GENETIC engineering ,HUMAN genetics ,GENETIC markers ,CELL transplantation ,PRODRUGS ,NERVE growth factor receptors - Abstract
Cell-fate control gene therapy (CFCGT)-based strategies can augment existing gene therapy and cell transplantation approaches by providing a safety element in the event of deleterious outcomes. Previously, we described a novel enzyme/prodrug combination for CFCGT. Here, we present results employing novel lentiviral constructs harboring sequences for truncated surface molecules (CD19 or low-affinity nerve growth factor receptor) directly fused to that CFCGT cDNA (TmpkF105Y). This confers an enforced one-to-one correlation between cell marking and eradication functions. In-vitro analysis demonstrated the full functionality of the fusion product. Next, low-dose 3′-azido-3′-deoxythymidine (AZT) administration to non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice injected with transduced clonal K562 cells suppressed tumor growth; furthermore, one integrated vector on average was sufficient to mediate cytotoxicity. Further, in a murine xenogeneic leukemia-lymphoma model we also demonstrated in-vivo control over transduced Raji cells. Finally, in a proof-of-principle study to examine the utility of this cassette in combination with a therapeutic cDNA, we integrated this novel CFCGT fusion construct into a lentivector designed for treatment of Fabry disease. Transduction with this vector restored enzyme activity in Fabry cells and retained AZT sensitivity. In addition, human Fabry patient CD34
+ cells showed high transduction efficiencies and retained normal colony-generating capacity when compared with the non-transduced controls. These collective results demonstrated that this novel and broadly applicable fusion system may enhance general safety in gene- and cell-based therapies. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF